PF-Atlas › Treatments › Dasatinib + Quercetin

Dasatinib + Quercetin

Senolytic — clears p16+/p21+ senescent cells, reduces SASP

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase II
Evidence level
Level 2 (Phase II)
Mechanism class
Senolytic — clears p16+/p21+ senescent cells, reduces SASP
Timeline
2-3 years
Risk profile
Low-Medium
Developer
Mayo Clinic
Key researchers
J. Kirkland

Overview

First senolytic trial in IPF. Intermittent 3-day dosing. Improved 6MWD. Phase III design underway.

How Dasatinib + Quercetin fits into IPF treatment

Dasatinib + Quercetin is classified as Level 2 (Phase II) at the Phase II stage. Explore how it compares to other options and where it sits in the development pipeline:

Dasatinib drug profileSenolytic — clears p16+/p21+ senescent cells, reduces SASPClinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoAdmilparant / BMS-986278Rentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic Immunotherapy
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Dasatinib + Quercetin for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.